Adam Colborn of AMCP Gives a Legislative, Regulatory Update in the Pharmacy Space and Shares Concern on OOP Medicare Part D Copay Assistance | AMCP Nexus 2023
Adam Colborn, JD, director of Government Relations at AMCP, addressed topics at this year's AMCP Nexus conference in Orlando such as transparency, cost sharing mandates and variables that affect the supply and demand curve for pharmaceuticals within legislation at a federal, but mainly state level. Colborn also touched on the large PBM reform regulation happening currently in New York as it could be a model that other states can follow.
Part one of two
Adam Colborn, JD, director of Government Relations at AMCP, addressed topics at this year's AMCP Nexus in Orlando such as transparency, cost sharing mandates and variables that affect the supply and demand curve for pharmaceuticals within legislation at a federal, but mainly state level.
Colborn also touched on the large PBM reform regulation happening currently in New York as it could be a model that other states can follow.
In an interview with MHE, Colborn shared what AMCP is keeping their eyes on in terms of the IRA. He mentioned his team has shown concern over Medicare drug price negotiation and out-of-pocket "smoothing" or copay assistance for those under Medicare Part D.
Colborn added the OOP "smoothing" is could be a large burden for retail and community pharmacists as they are the patient’s point of contact.
"It raises questions about 'how will a part D plan react if a patient changes their plan or they are unable to pay the rest of their prescription cost under a smoothing arrangement," he said. "It's a good first step but there are a lot of questions that still remain to be answered."
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Addressing the Challenges of AI is Imperative | AMCP Nexus 2024
August 2nd 2025There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
AI Benefits PBMs, Health Plans and Formulary Decision Making | AMCP Nexus 2024
August 2nd 2025Health plans and PBMs are using AI to aggregate data, summarize information and enhance their formulary decision-making processes, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research.
Read More
How Technology Benefits Specialty Pharmacy | AMCP 2024
August 2nd 2025Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research, explains how technology identifies at-risk patients, coordinates medication refills and more.
Read More
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
August 2nd 2025The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
